TABLE 1.

Adult Effective Dose Coefficients and Relative Differences Compared Among MIRDcalc, IDAC-Dose, and ICRP Publication 128

Radiopharmaceutical	Effective dose coefficient (mSv/MBq)
Radiopharmaceutical	MIRDcalc	IDAC-Dose	OLINDA	ICRP 128	$\text{[math]}$	$\text{[math]}$	$\text{[math]}$	$\text{[math]}$	$\text{[math]}$	$\text{[math]}$
¹¹¹In-octreotide	5.49E−02	5.38E−02	5.89E−02	5.40E−02	−2.0	−2.0%	7.0	7.3%	−1.7	−1.6%
¹²³I-ioflupane	2.50E−02	2.36E−02	2.16E−02	2.50E−02	−5.8	−5.6%	−15	−14%	0.00	0.00%
¹²³I-NaI capsules (high thyroid uptake)	2.45E−01	2.45E−01	2.77E−01	3.00E−01	0.00	0.00%	12	13%	20	22%
¹²³I-NaI capsules (thyroid blocked)	3.04E−02	3.02E−02	2.04E−02	3.70E−02	−0.66	−0.7%	−40	−33%	20	22%
¹³¹I-NaI capsules (high thyroid uptake)	2.17E+01	2.16E+01	2.64E+01	2.90E+01	−0.46	−0.50%	20	22%	29	34%
¹³¹I-NaI (thyroid blocked)	2.10E−01	2.08E−01	1.55E−01	2.80E−01	−0.96	−1.0%	−30	−26%	29	33%
¹³³Xe gas	1.99E−04	1.64E−04	1.86E−04	1.80E−04	−19	−18%	−6.8	−6.5%	−10	−9.5%
¹³³Xe gas (rebreathing for 10 min)	1.27E−03	1.21E−03	1.11E−03	1.10E−03	−4.8	−4.7%	−13	−13%	−14	−13%
¹⁴C-urea, Heliobacter positive	8.68E−02	7.75E−02	8.93E−02	8.10E−02	−11	−11%	2.8	2.9%	−6.9	−6.7%
¹⁴C-urea, normal case	2.42E−02	2.16E−02	2.93E−02	3.10E−02	−11	−11%	19	21%	25	28%
¹⁸F-FDG	1.67E−02	1.61E−02	1.92E−02	1.90E−02	−3.7	−3.6%	14	15%	13	14%
¹⁸F-NaF	1.30E−02	1.28E−02	1.65E−02	1.70E−02	−1.6	−1.5%	24	27%	27	31%
²⁰¹Tl-TlCl	1.13E−01	1.09E−01	8.47E−02	1.40E−01	−3.6	−3.5%	−29	−25%	21	24%
⁶⁷Ga-citrate	9.43E−02	8.97E−02	8.72E−02	1.00E−01	−5.0	−4.9%	−7.8	−7.5%	5.9	6.0%
⁸²Rb-chloride	1.05E−03	1.00E−03	7.77E−04	1.10E−03	−4.9	−4.8%	−30	−26%	4.7	4.8%
^99mTc-DMSA	7.02E−03	6.92E−03	7.24E−03	8.80E−03	−1.4	−1.4%	3.1	3.1%	23	25%
^99mTc-DTPA	3.37E−03	3.26E−03	4.57E−03	4.90E−03	−3.3	−3.3%	30	36%	37	45%
^99mTc-ECD	5.56E−03	5.52E−03	5.08E−03	7.70E−03	−0.72	−0.70%	−9.0	−8.6%	33	39%
^99mTc-iminodiacetic acid derivatives	9.44E−03	9.55E−03	3.84E−03	1.60E−02	1.2	1.2%	−90	−59%	53	70%
^99mTc-macroaggregated albumin	1.40E−02	1.15E−02	1.37E−02	1.10E−02	−20	−18%	−2.2	−2.1%	−24	−21%
^99mTc-MAG3	4.12E−03	4.09E−03	6.38E−03	7.00E−03	−0.73	−0.70%	44	55%	53	70%
^99mTc-sestamibi, exercise	6.19E−03	6.03E−03	3.74E−03	7.90E−03	−2.6	−2.6%	−50	−40%	24	28%
^99mTc-sestamibi, rest	7.09E−03	6.89E−03	4.64E−03	9.00E−03	−2.9	−2.8%	−42	−35%	24	27%
^99mTc-HMPAO	8.35E−03	7.99E−03	7.10E−03	9.30E−03	−4.4	−4.3%	−16	−15%	11	11%
^99mTc sulfur colloid	1.10E−02	1.09E−02	1.11E−02	9.10E−03	−0.91	−0.90%	0.90	0.90%	−19	−17%
^99mTc-pertechnetate, with blocking agent	4.07E−03	3.78E−03	4.47E−03	4.60E−03	−7.4	−7.1%	9.4	9.8%	12	13%
^99mTc-pertechnetate, no blocking agent	9.99E−03	9.87E−03	4.24E−03	1.30E−02	−1.2	−1.2%	−86	−58%	26	30%
^99mTc-MDP	4.32E−03	4.25E−03	5.10E−03	4.90E−03	−1.6	−1.6%	17	18%	13	13%
^99mTc-tetrofosmin, exercise	5.63E−03	5.37E−03	4.51E−03	6.90E−03	−4.7	−4.6%	−22	−20%	20	23%
^99mTc-tetrofosmin, rest	6.09E−03	5.89E−03	4.56E−03	8.00E−03	−3.3	−3.3%	−29	−25%	27	31%

Fluorodeoxyglucose (FDG), dimercaptosuccinic acid (DMSA), diethylenetriaminepentaacetic acid (DTPA), ethylenedicysteine diester (ECD), mercaptoacetyltriglycine (MAG3), hexamethylpropyleneamine oxime (HMPAO), methyl diphosphonate (MDP).